Searched for
BIOCON VALUATIONS
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- The 20 stocks mutual funds are buying with Rs 1 lakh crore to defy historic FII sellingIndian mutual funds are investing Rs 1.07 lakh crore in 20 key stocks to counter historic FII selling. They are focusing on large-cap priva...
- Ahead of Market: 10 things that will decide stock market action on ThursdayBenchmark indices closed marginally higher on Wednesday, led by gains in banking and auto shares, while IT and FMCG stocks capped advances....
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under reviewBiocon is exploring merging its biosimilars arm, Biocon Biologics, with itself, potentially valuing the unit at $4.5 billion. The company i...
- Biocon denies plans to sell $1.5 billion generic API businessBiocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valu...
- Viatris deal pinches Biocon, but may prove a good betThe $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...
- Can Serum deal provide a booster dose to Biocon's target price?The Serum alliance would give Biocon Biologics' access to 100 million doses of vaccines per annum for 15 years with commercialisation right...
- Biocon gains 2% as arm receives Rs 555 crore equity investment from ADQKiran Mazumdar-Shaw, Executive Chairperson at Biocon in a company filing to BSE said, "We welcome ADQ as our investment partner as we pursu...
- Biocon Biologics approves primary equity investment by ADQ worth Rs 555 croreAs per the terms of the proposed agreement, ADQ will invest Rs 555 Crore for a 1.80 per cent minority stake in the biosimilar business, val...
- Biocon Biologics eyes $200m, plans IPO in 2 years: Mazumdar-ShawIt looks to build a pipeline of 28 biosimilars across global markets in three phases.
- Biocon has little room to slip up after strong 2016At the end of 2015, 70% of analysts tracking the Biocon stock had a buy recommendation on it. Data from Bloomberg show that this number has...
- Syngene's valuations are fair, investors need to invest in its growth story: Kiran Mazumdar-ShawIn an interview with ET Now, Kiran Mazumdar-Shaw, CMD, Biocon, talks about the Syngene IPO and the growth prospects involved.
- Biocon Q1 net jumps 23 per cent to Rs 126 croreThe company's net sales grew by 15 per cent at Rs 857 crore for the period under review as compared to Rs 742 crore in the year-ago period,...
- Syngene dragged too far as value proposition; avoid Biocon: Prakash DiwanWhile Syngene has a healthy pipeline of biosimilars, the monetisation of some of the molecules could take up to six years, says Diwan.
- Biocon completes 10 per cent stake sale in SyngeneBiotechnology major Biocon today concluded sale of 10 per cent stake in its research arm Syngene for Rs 380 crore to IVF Trustee Company Pr...
- Positive on Torrent Pharma, Biocon & Dr Reddy's: Prashasta SethIn a chat with ET Now, Prashasta Seth, Senior Fund Manager, IIFL Wealth, shares his views about the pharma stocks.
- Private equity firm GE Capital pays Rs 125 crore for 7.7% stake in Biocon SyngeneGE Capital, the private equity arm of GE, on Wednesday picked up 7.69% in Syngene, the research services subsidiary of biotech firm Biocon,...
- GE capital picks up 7.69% in Biocon's Syngene for Rs 125 croreThe total valuation of Syngene with this investment stands at Rs 1600 cr. Following the news, Biocon shares jumped by over 3%.
Load More
